Vivekanand Jha's Publications

About Vivekanand Jha's Publications

Executive Director, The George Institute for Global Health, India
  • MD,
  • DM,
  • FRCP,
  • FAMS

  • Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases

    Kidney International Date published:

  • KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

    Kidney International Date published:

  • The High Mortality and Impact of Vaccination on COVID-19 in Hemodialysis Population in India During the Second Wave

    Kidney International Reports Date published:

  • Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy

    Kidney International Reports Date published:

  • Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019

    The Lancet Date published:

  • Membranous nephropathy

    Nature Reviews Disease Primers Date published:

  • Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trial

    Acta Anaesthesiologica Scandinavica Date published:

  • Serum catalytic iron and progression of chronic kidney disease: findings from the ICKD study

    Nephrology Dialysis Transplantation Date published:

  • Итоговое резюме KDIGO 2018 по гепатиту С для рекомендаций по ХБП: достижения в оценке и менеджменте

    KIDNEYS Date published:

  • Prescription Practices in Patients With Mild to Moderate CKD in India

    Kidney International Reports Date published:

  • Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases

    The Lancet Gastroenterology & Hepatology Date published:

  • Low-value medical care in the pandemic-is this what the doctor ordered?

    The Lancet Global Health Date published:

  • Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial

    Trials Date published:

  • Treatment preferences for primary membranous nephropathy: Results of a multinational survey among nephrologists in the South Asia Pacific region

    Nephrology Date published:

  • Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

    Unknown Date published:

  • The Indian Chronic Kidney Disease (ICKD) study: baseline characteristics

    Clinical Kidney Journal Date published: